Awaiting data from an ongoing Phase II trial of Locteron, a controlled-release interferon-alpha candidate for hepatitis C, Biolex Therapeutics Inc. closed a $30 million Series C round to advance that compound into Phase III. (BioWorld Today)
Awaiting data from an ongoing Phase II trial of Locteron, a controlled-release interferon-alpha candidate for hepatitis C, Biolex Therapeutics Inc. closed a $30 million Series C round to advance that compound into Phase III. (BioWorld Today)
Awaiting results from the final of four pivotal studies of its iron replacement therapeutic ferumoxytol, Cambridge, Mass.-based Advanced Magnetics Inc. is raising $162.9 million. (BioWorld Today)
Awaiting results from the final of four pivotal studies of its iron replacement therapeutic ferumoxytol, Cambridge, Mass.-based Advanced Magnetics Inc. is raising $162.9 million. (BioWorld Today)
In its largest financing round to date, QuatRx Pharmaceuticals Co. brought in $44 million in a Series E round to support ongoing clinical development of two endocrine programs, including a Phase III-stage selective estrogen receptor modulator for vaginal atrophy, and an early clinical-stage lipid-lowering compound. (BioWorld Today)
In its largest financing round to date, QuatRx Pharmaceuticals Co. brought in $44 million in a Series E round to support ongoing clinical development of two endocrine programs, including a Phase III-stage selective estrogen receptor modulator for vaginal atrophy, and an early clinical-stage lipid-lowering compound. (BioWorld Today)
